Urogen Pharma Ltd (NASDAQ:URGN) has received an average recommendation of “Buy” from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $65.25.
URGN has been the topic of several recent analyst reports. Oppenheimer set a $75.00 target price on Urogen Pharma and gave the stock a “buy” rating in a report on Tuesday, August 14th. Stifel Nicolaus initiated coverage on Urogen Pharma in a report on Thursday, September 13th. They issued a “buy” rating and a $70.00 target price on the stock. Finally, Cowen reissued a “buy” rating on shares of Urogen Pharma in a report on Tuesday, August 14th.
A number of large investors have recently bought and sold shares of URGN. Quantbot Technologies LP acquired a new position in Urogen Pharma during the 1st quarter worth $174,000. UBS Group AG lifted its holdings in Urogen Pharma by 31.5% during the 1st quarter. UBS Group AG now owns 3,611 shares of the company’s stock worth $180,000 after buying an additional 865 shares in the last quarter. Barclays PLC acquired a new position in Urogen Pharma during the 1st quarter worth $1,242,000. ETF Managers Group LLC lifted its holdings in Urogen Pharma by 19.2% during the 1st quarter. ETF Managers Group LLC now owns 8,161 shares of the company’s stock worth $395,000 after buying an additional 1,316 shares in the last quarter. Finally, DAFNA Capital Management LLC acquired a new position in Urogen Pharma during the 1st quarter worth $224,000. 71.11% of the stock is currently owned by hedge funds and other institutional investors.
Shares of URGN opened at $45.16 on Friday. The company has a market capitalization of $649.48 million, a PE ratio of -21.10 and a beta of 2.08. Urogen Pharma has a one year low of $25.56 and a one year high of $69.57.
Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Tuesday, August 14th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.25). The business had revenue of $0.36 million during the quarter. Urogen Pharma had a negative return on equity of 44.24% and a negative net margin of 470.54%. Research analysts anticipate that Urogen Pharma will post -4.12 earnings per share for the current fiscal year.
About Urogen Pharma
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Read More: Technical Analysis
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.